Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ProQR Therapeutics N.V. (PRQR : NSDQ)

• Company Description    ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. Number of Employees: 187

• Price / Volume Information    Yesterday's Closing Price: $1.37 Daily Weekly Monthly 20 Day Moving Average: 313,478 shares Shares Outstanding: 105.36 (millions) Market Capitalization: $144.35 (millions) Beta: 0.21 52 Week High: $3.10 52 Week Low: $1.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.84% -6.94% 12 Week -31.16% -25.86% Year To Date -32.18% -27.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ZERNIKEDREEF 9 - LEIDEN,P7 2333 CK NLD ph: 31-88-166-7000 fax: - ir@proqr.com http://www.proqr.com

• General Corporate Information    Officers Daniel de Boer - Chief Executive Officer James Shannon - Chairman Dinko Valerio - Director Alison F. Lawton - Director Bart Filius - Director Peer Information ProQR Therapeutics N.V. (CORR.) ProQR Therapeutics N.V. (RSPI) ProQR Therapeutics N.V. (CGXP) ProQR Therapeutics N.V. (BGEN) ProQR Therapeutics N.V. (GTBP) ProQR Therapeutics N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N71542109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 105.36 Most Recent Split Date: (:1) Beta: 0.21 Market Capitalization: $144.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.58 Price/Cash Flow: - Price / Sales: 7.96 EPS Growth vs. Year Ago Period: 10.00% vs. Previous Quarter: 25.00% Sales Growth vs. Year Ago Period: 18.76% vs. Previous Quarter: 61.98% ROE 12/31/25 - -65.89 09/30/25 - -58.70 06/30/25 - -61.25 ROA 12/31/25 - -31.53 09/30/25 - -29.37 06/30/25 - -28.13 Current Ratio 12/31/25 - 3.09 09/30/25 - 3.36 06/30/25 - 3.76 Quick Ratio 12/31/25 - 3.09 09/30/25 - 3.36 06/30/25 - 3.76 Operating Margin 12/31/25 - -255.83 09/30/25 - -273.20 06/30/25 - -238.52 Net Margin 12/31/25 - -255.83 09/30/25 - -273.20 06/30/25 - -238.52 Pre-Tax Margin 12/31/25 - -265.09 09/30/25 - -273.13 06/30/25 - -238.49 Book Value 12/31/25 - 0.53 09/30/25 - 0.63 06/30/25 - 0.72 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©